Evercore Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories (NYSE:ABT) had its price objective dropped by analysts at Evercore from $138.00 to $134.00 in a report issued on Monday,MarketScreener reports. The brokerage currently has an “outperform” rating on the healthcare product maker’s stock. Evercore’s price target would indicate a potential upside of 30.99% from the stock’s previous close.

ABT has been the topic of a number of other reports. Weiss Ratings cut shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Leerink Partners lowered their target price on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research report on Friday, January 30th. Sanford C. Bernstein lowered their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. BTIG Research dropped their price target on shares of Abbott Laboratories from $140.00 to $131.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Finally, Argus lowered their price objective on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $135.47.

Abbott Laboratories Stock Down 0.6%

Abbott Laboratories stock opened at $102.30 on Monday. Abbott Laboratories has a twelve month low of $100.88 and a twelve month high of $139.06. The stock has a market cap of $178.16 billion, a P/E ratio of 27.50, a P/E/G ratio of 1.64 and a beta of 0.79. The company’s 50-day moving average price is $109.35 and its two-hundred day moving average price is $120.71. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same period last year, the firm earned $1.34 earnings per share. Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Insider Buying and Selling

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the sale, the senior vice president owned 39,164 shares in the company, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock worth $353,097 over the last quarter. 0.46% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. J. Derek Lewis & Associates Inc. purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth about $1,992,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Stance Capital LLC increased its stake in shares of Abbott Laboratories by 12.8% in the 4th quarter. Stance Capital LLC now owns 11,339 shares of the healthcare product maker’s stock valued at $1,421,000 after purchasing an additional 1,291 shares in the last quarter. Cornerstone Planning LLC acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $2,858,000. Finally, Rockefeller Capital Management L.P. raised its stake in shares of Abbott Laboratories by 27.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,377,659 shares of the healthcare product maker’s stock worth $172,607,000 after buying an additional 297,268 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.